Supernus’ depression drug shows ‘rapid’ onset in mid-stage test
Supernus Pharmaceuticals’ mTORC1 activator has cleared a small trial in patients with major depressive disorder, potentially bringing the biotech one step closer to offering a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
